13:01 , Jul 1, 2019 |  BC Extra  |  Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding. It’s the second time the partners have...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
19:26 , Apr 30, 2019 |  BC Extra  |  Clinical News

April 30 Clinical Quick Takes: Xencor, Axovant, Cell Medica

Partial hold lifted on Xencor's blood cancer bispecific  FDA lifted a partial clinical hold on a Phase I trial of XmAb14045 from Xencor Inc. (NASDAQ:XNCR), which is evaluating the bispecific antibody against CD3 and CD123...
04:45 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
23:15 , Nov 30, 2018 |  BC Extra  |  Company News

Management tracks: Inflazome, Clementia

Two weeks after raising €40 million ($45.7 million) in a series B round in preparation for its first clinical trials which are slated for next year, Inflazome Ltd. (Dublin, Ireland) hired Thomas Jung as its...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
17:38 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Cell Medica doses first neuroblastoma patient with NK cell therapy

Cell Medica Ltd. (London, U.K.) dosed the first patient in the open-label, U.S. Phase I GINAKIT2 trial of CMD-501 to treat relapsed or refractory pediatric neuroblastoma, which the company said marks the first use of...
22:18 , Aug 1, 2018 |  BC Extra  |  Company News

Management tracks: Hologic, Tricidia

Hologic Inc. (NASDAQ:HOLX) said Bob McMahon has departed as CFO to become CFO at Agilent Technologies Inc. (NYSE:A). The diagnostics company promoted Chief Accounting Officer Karleen Oberton to CFO. Metabolic acidosis play Tricida Inc. (NASDAQ:TCDA)...
21:37 , Jun 11, 2018 |  BC Extra  |  Company News

Management tracks: Arbutus, Cancer Research UK

HBV company Arbutus Biopharma Corp. (NASDAQ:ABUS) said CFO Koert VandenEnden is stepping down. He is succeeded by David Hastings, who was CFO and EVP at Unilife Corp. Unilife went bankrupt in 2017. Cancer Research UK...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...